<DOC>
	<DOCNO>NCT00803244</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety sublingual tablet grass pollen allergen extract initiate 2 month grass pollen season compare placebo reduction rhinoconjunctivitis symptom rescue medication usage .</brief_summary>
	<brief_title>Safety Efficacy Phase III Study 300 IR SLIT Patients Suffering From Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description>To assess efficacy sublingual tablet grass pollen allergen extract initiate 2 month grass pollen season : - The Average Adjusted Symptom Score ( AASS ) . To document safety treatment .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female outpatient age 12 65 year ( inclusive ) . 2 . Patients grass pollenrelated allergic rhinoconjunctivitis least last two grass pollen season . 3 . Positive SPT 4 . RRTSS previous pollen season great equal 12 possible 18 . 1 . Positive SPT seasonal allergen present grass pollen season 2 . Patients clinically significant confound symptom allergy allergen 3 . Significant symptomatic perennial allergy due allergen patient regularly expose . 4 . Patients moderate severe persistent asthma ( Global Initiative Asthma [ GINA ] 3 4 ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>allergic rhinoconjunctivitis</keyword>
</DOC>